Kun Huang
Chongqing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Longitudinal Interferon-γ Release Assay Changes in Psoriasis Treated With Interleukin Inhibitors: A Single-Center Real-World Cohort Study in China.
Journal: Journal of the American Academy of Dermatology
Published: April 07, 2026
Genotype-Phenotype Correlations and Clinical Outcomes of Spesolimab in Acrodermatitis Continua of Hallopeau: A Multicenter Retrospective Cohort Study.
Journal: Psoriasis (Auckland, N.Z.)
Published: April 01, 2026
Pneumococcal Endopeptidase O Attenuates Colitis by Inhibiting the Macrophage-CCL2 Axis and Reshaping Gut Microbiota.
Journal: Journal of inflammation research
Published: February 17, 2026
SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.
Journal: Frontiers in immunology
Published: February 13, 2026
A 76-week real-world multidimensional analysis of guselkumab in moderate to severe plaque psoriasis: a retrospective cohort study based on Chinese clinical practice standards.
Journal: Frontiers in immunology
Published: August 13, 2025
Correction: Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial.
Journal: Dermatology and therapy
Published: July 24, 2025
Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial.
Journal: Dermatology and therapy
Published: April 22, 2025
A Review on the Mechanisms and Clinical Advances of JAK Inhibitors in the Treatment of Rosacea.
Journal: Journal of cutaneous medicine and surgery
Published: March 28, 2025
Superior efficacy and comparable safety of calcipotriol plus betamethasone dipropionate foam vs. ointment in Chinese patients with plaque psoriasis: A randomized phase 3 trial.
Journal: Chinese medical journal
Published: March 21, 2025
Retraction Note: Targeting HIF-1α/NOTCH1 pathway eliminates CD44+ cancer stem-like cell phenotypes, malignancy, and resistance to therapy in head and neck squamous cell carcinoma.
Journal: Oncogene
Published: February 27, 2025
Efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled trial.
Journal: Chinese medical journal
Published: December 13, 2024
Successful Guselkumab Treatment in a Patient with Comorbid Psoriasis and Amyotrophic Lateral Sclerosis: A Case Study and Literature Review.
Journal: Clinical, cosmetic and investigational dermatology
Published: November 27, 2024
Last Updated: 09/26/2026